Animal & Veterinary
FDA Extends Comment Period on AquAdvantage Salmon Documents
February 13, 2013
The U.S. Food and Drug Administration announced today that it is extending for 60 days the comment period for the draft Environmental Assessment (EA) and preliminary Finding of No Significant Impact (FONSI) pertaining to AquaBounty Technologies’ application for AquAdvantage Salmon. The comment period, originally slated to end on Feb. 25, 2013, now runs until April 26, 2013.
AquAdvantage Salmon are Atlantic salmon that have been genetically engineered to reach a measure of growth commonly used in salmon aquaculture more rapidly than other farmed Atlantic salmon. This is commonly linked to “reaching market size” (about 2-5 kilograms or about 5-12 pounds) in less time than other farmed salmon.
The draft EA and preliminary FONSI are one step in FDA’s evaluation of the AquAdvantage Salmon and do not indicate an approval of the application. The National Environmental Policy Act of 1969 (NEPA) requires FDA and other federal agencies to perform such assessments whenever a major Federal action is taken.
Notice of Extension of Comment Period; Draft Environmental Assessment and Preliminary Finding of No Significant Impact Concerning a Genetically Engineered Atlantic Salmon
- Original Federal Register Notice; Request for Comments; Draft Environmental Assessment and Preliminary Finding of No Significant Impact Concerning a Genetically Engineered Atlantic Salmon
Text of Draft Environmental Assessment for Genetically Engineered Atlantic Salmon Text of Finding of No Significant Impact for Genetically Engineered Atlantic Salmon
- How to Comment
Regulations.gov: Docket Number FDA-2011-N-0899